NCT04629105View on ClinicalTrials.gov

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

July 31, 2025

Conditions
ARDS, HumanCovid19
Interventions
BIOLOGICAL

Longeveron Mesenchymal Stem Cells (LMSCs)

Longeveron Mesenchymal Stem Cells (LMSCs)

OTHER

Placebo

Placebo

Trial Locations (3)

21201

University of Maryland Medical Center, Baltimore

27157

Wake Forest Baptist Medical Center, Winston-Salem

33125

Miami VA Healthcare System, Miami

Sponsors

Lead Sponsor

Longeveron Inc.
All Listed Sponsors
lead

Longeveron Inc.

INDUSTRY

NCT04629105 - Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER) | Biotech Hunter | Biotech Hunter